3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
8
Lymphoma, Mantle-Cell
4
Lymphoma
3
Waldenstrom Macroglobulinemia
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Mature B-Cell Malignancies
1
Lymphoma, B-Cell
1
Leukemia, B-Cell
1
Hematologic Neoplasms
1
Hematologic Diseases
1
B-cell Malignancies
1
Interventions
venetoclax
4
ibrutinib
4
obinutuzumab
3
fludarabine phosphate
3
fludarabine
3
Mesna
3
Cyclophosphamide
3
Whole-Body Irradiation
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Mycophenolic Acid
2
Melphalan
2
Busulfan
2
zanubrutinib
1
ricolinostat
1
idelalisib
1
acalabrutinib
1
Bone Marrow Transplantation
1
Bendamustine Hydrochloride
1
ARQ531
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Leukemia, B-Cell
×
zanubrutinib
×
Clear all
NCT04515238
2025-06-10
CLL2-BZAG
German CLL Study Group
Phase 2
Active not recruiting
42 enrolled